CYP7A1 and metabolic dysfunction-associated steatotic liver disease: Since CYP7A1 is the rate-limiting enzyme in bile acid synthesis, OCA can inhibit bile acid synthesis and is used to treat primary biliary cholangitis and non-alcoholic fatty liver disease [24].